VRCI — Verici Dx Share Price
Last trade - 00:00- £7.58m
- £2.22m
- $1.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.98 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -50.1% | ||
| Return on Equity | -58.12% | ||
| Operating Margin | -114.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 1.01 | 4.02 | 11.65 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including sub-clinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- April 22nd, 2020
- Public Since
- November 3rd, 2020
- No. of Employees
- 19
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- London Stock Exchange
- Shares in Issue
- 242,541,467
- Address
- 393 Nichol Mill Lane, Suite 200, FRANKLIN, 37067
- Web
- https://vericidx.com/
- Phone
- Auditors
- Crowe U.K. LLP
Latest News for VRCI
Upcoming Events for VRCI
Full Year 2024 Verici DX PLC Earnings Release
Similar to VRCI
Abingdon Health
London Stock Exchange
Advanced Medical Solutions
London Stock Exchange
Angle
London Stock Exchange
Aoti
London Stock Exchange
Aptamer
London Stock Exchange
FAQ
As of Today at 22:58 UTC, shares in Verici Dx are trading at 3.13p. This share price information is delayed by 15 minutes.
Shares in Verici Dx last closed at 3.13p and the price had moved by -63.24% over the past 365 days. In terms of relative price strength the Verici Dx share price has underperformed the FTSE All Share Index by -66.73% over the past year.
The overall consensus recommendation for Verici Dx is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVerici Dx does not currently pay a dividend.
Verici Dx does not currently pay a dividend.
Verici Dx does not currently pay a dividend.
To buy shares in Verici Dx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 3.13p, shares in Verici Dx had a market capitalisation of £7.58m.
Here are the trading details for Verici Dx:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: VRCI
Based on an overall assessment of its quality, value and momentum Verici Dx is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Verici Dx is 19.71p. That is 530.56% above the last closing price of 3.13p.
Analysts covering Verici Dx currently have a consensus Earnings Per Share (EPS) forecast of -$0.03 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Verici Dx. Over the past six months, its share price has underperformed the FTSE All Share Index by -59.75%.
As of the last closing price of 3.13p, shares in Verici Dx were trading -55.25% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Verici Dx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at 3.13p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Verici Dx's directors